Navigating IgA Nephropathy

If your kidneys were a coffee shop, the glomeruli would be the tiny, hardworking baristas filtering your blood all day long.
In IgA nephropathy (IgAN)also called Berger diseaseyour immune system accidentally drops “sticky” antibody clumps (IgA-based immune complexes)
into those filters. The result is inflammation, leaky filtration (blood and protein in the urine), andsometimesslow, stubborn scarring over time.
Not exactly the kind of “extra foam” anyone asked for.

This guide is designed to help you understand what IgA nephropathy is, how it’s diagnosed, what the numbers mean, and how treatment decisions are typically made.
It’s educationalnot a substitute for your clinician’s advicebecause kidneys, like houseplants, do best with personalized care (and fewer surprises).

What IgA Nephropathy Actually Is (In Plain English)

IgA nephropathy is an immune-mediated kidney disease where IgA (immunoglobulin A), an antibody that normally helps defend against infections,
accumulates in the kidney’s filtering units (glomeruli). Those deposits trigger inflammation. Over time, inflammation can cause scarring,
and scarring can reduce how well your kidneys filter waste and manage fluid balance.

The hallmark clues are:

• Hematuria (blood in urine)sometimes visible (tea- or cola-colored), sometimes only seen on a lab test
• Proteinuria (protein in urine)often noticed as foamy urine or flagged on urine testing
• Changes in kidney functiontracked with bloodwork (eGFR/creatinine) over time

Who Gets IgAN, and Why Does It Happen?

IgA nephropathy is diagnosed around the world and often shows up in young adulthood, but it can appear at other ages too.
The “why” is complex. Many experts describe a multi-step process in which the immune system makes an abnormal form of IgA,
the body forms antibodies against it, immune complexes circulate, and then those complexes deposit in the kidneysparking inflammation.

IgAN isn’t something you “catch,” and it isn’t caused by one single food, supplement, or stressful week (though stress can make everything feel louder).
It sometimes flares after respiratory or gastrointestinal infectionsthink: “I had a bad cold, and then my urine looked like iced tea.”
Family history can matter for some people, suggesting genetic susceptibility, but many patients have no clear hereditary pattern.

Symptoms: Sometimes Loud, Sometimes Sneaky

One reason IgAN can be tricky: it may cause few symptoms until kidney damage is underway. When symptoms do show up, common ones include:

• Visible blood in urine, often after an infection
• Foamy urine (a clue for higher protein levels)
• Swelling in ankles/feet or around the eyes (from fluid retention)
• High blood pressure
• Fatigue, especially if kidney function declines
• Flank or back discomfort (less specific, but sometimes reported)

Diagnosis: How Doctors Confirm It (and Rule Other Things Out)

Your clinician usually starts with a story and basic tests, then works toward confirmation. Typical steps include:

1) Urine testing

A urinalysis can detect blood and protein. Quantifying protein matters, so you’ll often see tests like:
UPCR (urine protein-to-creatinine ratio) or UACR (albumin-to-creatinine ratio).
These provide a “protein leak score” without making you carry around a 24-hour urine jug like a very odd accessory.

2) Blood testing

Bloodwork estimates kidney function using creatinine and calculates eGFR.
Doctors may also check cholesterol, electrolytes, and other labs to evaluate overall kidney health and contributing risks.

3) Blood pressure and cardiovascular risk check

Blood pressure isn’t just a side detailit’s a major driver of progression in chronic kidney disease.
Your care team may also address cholesterol and other heart-health factors, because kidneys and hearts tend to be close friends (sometimes unhelpfully so).

4) Kidney biopsy (the “yes/no” test)

A kidney biopsy is the definitive way to diagnose IgA nephropathy, because it can directly show IgA deposits and patterns of inflammation/scarring
under a microscope. It also helps determine prognosis and guide treatment intensity.

Pathology reports often reference the Oxford MEST-C scoring system, which summarizes specific biopsy features linked to outcomes.
You don’t need to memorize the acronym, but you can absolutely ask your nephrologist what your biopsy showed and what it implies for your risk level.

Understanding Your “Kidney Dashboard”: Key Numbers to Track

IgAN management is often about trendswhere your numbers are goingrather than one “good” or “bad” result.
Here’s what commonly matters most:

• Proteinuria (UPCR/UACR or 24-hour protein):
  Persistent higher protein in urine is one of the strongest predictors of progressionand a key treatment target.
• eGFR:
  An estimate of filtering capacity. A slow decline might be manageable; a faster drop may push your team toward more aggressive therapy.
• Blood pressure:
  Often a “make-or-break” variable. Tight control can reduce stress on the glomeruli and help lower proteinuria.
• Biopsy findings:
  Degree of scarring and active inflammation can influence risk and medication choices.

Prognosis: What “Progression” Really Means

IgA nephropathy is famously variable. Some people have mild disease that stays stable for decades.
Others progress faster and may eventually develop advanced chronic kidney disease (CKD) or kidney failure requiring dialysis or transplant.

Population studies often cite that a substantial minority of patients progress to kidney failure over 10–20 years, but the range is wide.
The good news: risk prediction and treatment options have improved, and today’s IgAN care is far more proactive than it used to be.
The most important point is this: your individual risk is best estimated by your proteinuria level, kidney function trend, blood pressure, and biopsy results.

Treatment: The “Support First, Escalate When Needed” Game Plan

IgAN treatment generally follows a stepwise approach:
start with optimized supportive care for kidney protection, then consider IgAN-targeted or immune-modulating therapies if risk remains high.

Step 1: Optimized supportive care (the foundation)

Supportive care isn’t “doing nothing.” It’s doing the proven, kidney-protective work consistentlybecause kidneys love boring routines.
Common pillars include:

• Blood pressure control (often aiming for a lower target, individualized to the patient)
• ACE inhibitors or ARBs to reduce proteinuria and protect kidney filterseven if blood pressure is normal
• Lower sodium intake (salt can raise BP and worsen fluid retention)
• Healthy weight, regular activity, and smoking cessation
• Cholesterol management when appropriate
• Avoiding kidney stressors (e.g., frequent NSAID use unless your clinician says otherwise)

Step 2: Add-on kidney-protective medications (often considered in CKD)

Many patients with proteinuric CKDsometimes including IgANmay be considered for medications like SGLT2 inhibitors
(commonly known from diabetes care, but increasingly used for kidney protection even without diabetes in certain patients).
Whether you’re a candidate depends on your eGFR, albumin/protein levels, blood pressure, and overall profile.

Step 3: If risk stays high, consider IgAN-targeted or immune-directed therapy

If proteinuria stays meaningfully elevated despite a period of optimized supportive care, your nephrologist may talk about treatments that address IgAN more directly.
Options have expanded quickly in recent years, and choice depends on your risk level, comorbidities, and tolerance for side effects.

Option A: Corticosteroids (selected patients)

Traditional systemic steroids (like prednisone) can reduce inflammation and proteinuria in some higher-risk patients.
But they also come with real risksweight gain, mood changes, blood sugar issues, infection risk, bone effectsso clinicians weigh benefits carefully.
You’ll often hear the phrase: “We use steroids when the risk of progression is high enough to justify the trade-offs.”

Option B: Targeted-release budesonide (Tarpeyo)

Tarpeyo is an oral, targeted-release budesonide designed to act on gut-associated immune tissue, which is relevant to IgAN biology.
It received accelerated approval earlier and later received full FDA approval in late 2023 for adults with primary IgAN at risk of progression.
It’s not a fit for everyone, but it’s an important option that can reduce proteinuria and has shown benefit on kidney function outcomes in confirmatory data.

Option C: Sparsentan (Filspari)

Filspari (sparsentan) is a dual endothelin and angiotensin receptor antagonist approved under accelerated approval to reduce proteinuria
in adults with primary IgAN at risk of rapid progression. Because it targets pathways involved in protein leakage and kidney injury,
it’s often discussed for patients with higher proteinuria levels despite foundational therapy.

Option D: Complement pathway inhibition (Fabhalta)

Fabhalta (iptacopan) received FDA accelerated approval for reducing proteinuria in adults with primary IgAN at risk of rapid progression.
It works by inhibiting part of the complement system, which is implicated in IgAN’s inflammatory cascade.
As with other newer IgAN therapies, accelerated approval is based on proteinuria reduction as a surrogate endpoint, with ongoing data collection for long-term benefit.

Option E: APRIL blockade (Voyxact)

Voyxact (sibeprenlimab-szsi) is an FDA accelerated approval option (late 2025) for reducing proteinuria in adults with primary IgAN at risk for progression.
It’s a subcutaneous injection dosed every four weeks and targets APRIL, a key signal that supports B-cell pathways involved in IgAN.
For some patients, the “at-home injection” convenience is a big deal; for others, it’s a hard pass. Either reaction is valid.

Important reality check: Not everyone needs these newer agents. Many patients do well on supportive care alone.
The goal is matching treatment intensity to riskstrong enough to protect your kidneys, not stronger than necessary.

Food, Lifestyle, and Daily Habits That Actually Matter

No diet “cures” IgAN, but lifestyle choices can meaningfully support kidney health and complement medication.
Your care team may recommend:

• Lower sodium (a practical step for BP and swelling)
• Protein intake that’s appropriate (not extreme; often individualized based on CKD stage and nutrition needs)
• Plant-forward eating and heart-healthy fats (kidney-friendly and cardiovascular-friendly often overlap)
• Regular activity (think consistency, not punishment)
• Sleep and stress management (not because stress “causes” IgAN, but because it makes adherence harder)

Supplements are a frequent question. Fish oil has been studied in IgAN with mixed results. The bottom line:
don’t self-prescribe high-dose supplements without discussing it with your nephrology teamespecially because “natural” can still affect bleeding risk,
blood pressure, or medication interactions.

Monitoring: How Often Do You Recheck Things?

Monitoring frequency depends on risk level. Many patients have regular checks of:
urine protein (UPCR/UACR), blood pressure, creatinine/eGFR, and sometimes additional labs depending on therapy.
If you start a newer IgAN agent or immunosuppressive approach, monitoring tends to become more frequentbecause safety matters as much as efficacy.

Dialysis and Transplant: The Part Nobody Wants to Google (But Everyone Should Understand)

Some people with IgAN progress to kidney failure and need dialysis or a kidney transplant to live.
The good news is that transplant outcomes are generally strong, and many patients return to active, meaningful lives.
IgAN can recur after transplant in some cases, so transplant recipients still require follow-up.
If your kidney function is declining, early education and planning can reduce fear and improve controlbecause “prepared” beats “surprised” every time.

FAQ: Quick Answers to Common IgAN Questions

Is IgA nephropathy the same as IgA vasculitis?

Related, but not identical. IgA vasculitis (formerly Henoch-Schönlein purpura) can involve IgA-driven inflammation in blood vessels and may affect kidneys.
IgA nephropathy refers specifically to IgA deposits in the kidney glomeruli.

Will I always see blood in my urine during a flare?

Not necessarily. Some people have visible hematuria during infections; others only have microscopic blood on testing.
That’s why routine lab monitoring matters even when you “feel fine.”

What’s the single most important modifiable factor?

For many patients, it’s proteinuria controlwhich often improves with ACE/ARB therapy, blood pressure control, and other supportive measures,
and may lead to escalation therapies if it stays high.

Can I exercise?

In most cases, yesand it’s beneficial. The right intensity depends on blood pressure, kidney function, anemia, and overall health.
Your clinician can advise if you should avoid very heavy lifting or certain supplements that sometimes accompany gym culture.

Conclusion: Your Kidneys Like a Plan

Navigating IgA nephropathy is a marathon with occasional plot twists. The strongest strategy is surprisingly consistent:
confirm the diagnosis, understand your risk profile, optimize supportive care, track the right markers, and escalate treatment when your risk warrants it.
The modern IgAN landscape includes more targeted therapies than ever, which means the conversation has shifted from “watch and wait”
to “measure, manage, and protect.”

If you take one thing away, let it be this: you don’t need to know everything about IgAN to do well
you just need to know your numbers, your next step, and who to call when something changes.

Experiences: What “Navigating IgAN” Feels Like in Real Life (and What Helps)

Ask ten people with IgA nephropathy what it’s like, and you’ll get eleven answersbecause the disease is unpredictable and humans are creative.
Still, patterns show up in how people cope, adapt, and regain a sense of control.

The first emotional speed bump is usually the name. “IgA nephropathy” sounds like something you’d need a secret decoder ring to understand.
Many people describe the early days as a crash course in lab acronyms: eGFR, UPCR, ACR, RAAS… plus the sudden realization that urine can be both a symptom and a report card.
One common tip: keep a simple note in your phone with your trendlinesblood pressure, proteinuria, eGFRand the date of each test.
It turns appointments from a pop quiz into a conversation.

The biopsy story is practically a genre. People often worry it will be unbearably painful or terrifying.
In reality, many describe it as “uncomfortable but doable,” followed by a weirdly intense period of waiting for results.
Some patients cope by asking the care team for a plain-English summary of the pathology findings:
“How much is active inflammation vs. scarring?” and “What does this mean for my risk over the next few years?”
That framing helps shift the focus from fear to decision-making.

Then comes the lifestyle phasethe part where salt turns into the villain of the story.
People who succeed long-term usually don’t attempt a perfect diet overnight.
They pick two or three high-impact changes: stop salting at the table, swap packaged snacks for lower-sodium options, and learn which restaurant meals are basically sodium novels.
A practical hack that comes up often: choose one “default” breakfast and one “default” lunch that are kidney-friendly and easy.
When life gets chaotic, defaults prevent backsliding.

Medication experiences vary, and that’s normal. Some patients feel nothing noticeable on ACE inhibitors or ARBsjust improved numbers.
Others deal with cough, dizziness, or changes in potassium that require dose adjustments.
People starting newer IgAN-targeted therapies often describe a different kind of learning curve:
scheduling labs, watching for side effects, and managing insurance approvals.
The coping skill here is advocacy without burnoutbringing a short list of questions, keeping copies of labs, and asking,
“What’s our target proteinuria goal, and what do we do if I don’t reach it?”

Socially, IgAN can be invisibleuntil it isn’t. Many patients look fine but feel tired, anxious, or overwhelmed by the constant monitoring.
Some find it helpful to have a one-sentence explanation for friends and coworkers:
“I have an immune-related kidney condition, so I do regular labs and manage blood pressure.”
It’s honest, not dramatic, and doesn’t invite a 45-minute debate about a miracle smoothie.

Finally, many long-term IgAN navigators share the same hard-won insight:
focus on what you can control, and build routines around it. You can’t will IgA deposits away,
but you can control follow-up, blood pressure habits, medication consistency, and the “small daily choices” that add up.
In a disease that sometimes feels random, structure is surprisingly comfortinglike giving your kidneys a reliable playlist to work to.